Rui Xu

Rui Xu

Auto-generated profile, based on publicly available information

Rui Xu

Bioanalytical Discovery & Development Sciences (BDDS), Preclinical Sciences & Translational Safety (PSTS), Research & Development (R&D), Janssen Pharmaceutica NV, A Johnson & Johnson Company, Beerse, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
RXRui Xu
Rui Xu
CHCarsten Höß
Carsten Höß
JSJakub M. Swiercz
Jakub M. Swiercz
DBDominique T. Brandt
Dominique T. Brandt
VLVeronika Lutz
Veronika Lutz
TWThomas Worzfeld
Thomas Worzfeld
Peptic ulcer disease is a frequent clinical problem with potentially serious complications such as bleeding or perforation. A decisive factor in the pathogenesis of peptic ulcers is gastric acid, the secretion of which is controlled by the hormone gastrin released from gastric G cells. However, the molecular mechanisms regulating gastrin plasma concentrations are poorly understood. Here, we identified a semaphorin-plexin signaling pathway that operates in gastric G cells to inhibit gastrin expression on a transcriptional level, thereby limiting food-stimulated gastrin release and gastric acid secretion. Using a systematic siRNA screening approach combined with biochemical, cell biology, and in vivo mouse experiments, we found that the RasGAP protein Rasal1 is a central mediator of plexin signal transduction, which suppresses gastrin expression through inactivation of the small GTPase R-Ras. Moreover, we show that Rasal1 is pathophysiologically relevant for the pathogenesis of peptic ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs), a main risk factor of peptic ulcers in humans. Last, we show that application of recombinant semaphorin 4D alleviates peptic ulcer disease in mice in vivo, demonstrating that this signaling pathway can be harnessed pharmacologically. This study unravels a mode of G cell regulation that is functionally important in gastric homeostasis and disease.

1 August 2024 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
RXRui Xu
Rui Xu
EEEmmanuel Njumbe Ediage
Emmanuel Njumbe Ediage
TVTom Verhaeghe
Tom Verhaeghe
JSJan Snoeys
Jan Snoeys
LDLieve Dillen
Lieve Dillen
In recent years, therapeutic siRNA projects are booming in the biotech and pharmaceutical industries. As these drugs act by silencing the target gene expression, a critical step is the binding of antisense strands of siRNA to RNA-induced silencing complex (RISC) and then degrading their target mRNA. However, data that we recently obtained suggest that double-stranded siRNA can also load to RISC. This brings a new understanding of the mechanism of RISC loading which may have a potential impact on how quantification of RISC loaded siRNA should be performed. By combining RNA immune precipitation and probe-based hybridization LC-fluorescence approach, we have developed a novel assay that can accurately quantify the RISC-bound antisense strand, irrespective of which form (double-stranded or single-stranded) is loaded on RISC. In addition, this novel assay can discriminate between the 5′-phosphorylated antisense (5′p-AS) and the nonphosphorylated forms, therefore specifically quantifying the RISC bound 5′p-AS. In comparison, stem-loop qPCR assay does not provide discrimination and accurate quantification when the oligonucleotide analyte exists as a mixture of double and single-stranded forms. Taking together, RISC loading assay with probe-hybridization LC-fluorescence technique would be a more accurate and specific quantitative approach for RISC-associated pharmacokinetic assessment.